Skip to main content

ORIGINAL RESEARCH article

Front. Cardiovasc. Med.
Sec. Cardiac Rhythmology
Volume 11 - 2024 | doi: 10.3389/fcvm.2024.1495377

Effect of low-dose rivaroxaban on bleeding events in low-weight patients with nonvalvular atrial fibrillation: a retrospective propensity score-matched cohort study

Provisionally accepted
Yuan Liu Yuan Liu 1Hengli Lai Hengli Lai 2*Zhenhuan Chen Zhenhuan Chen 2Ganwei Xiong Ganwei Xiong 3*
  • 1 Jiangxi Medical College, Nanchang University, Nanchang, China
  • 2 Department of Cardiology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi Province, China
  • 3 The First People's Hospital of Xiushui County, Jiujiang, China

The final, formatted version of the article will be published soon.

    To investigate the effect of low-dose rivaroxaban on bleeding events in low-weight patients with nonvalvular atrial fibrillation.A retrospective study was conducted in patients with nonvalvular atrial fibrillation (weight≤60kg) who were admitted to the Department of Cardiology of Jiangxi Provincial People's Hospital from June 1, 2022, to December 12, 2022 and received anticoagulant therapy with rivaroxaban. The patients were divided into standard-dose group (15-20 mg) and low-dose group (10-15 mg). The patients were followed up for an average of 15 months by outpatient examination, telephone followup, or medical record inquiry of readmission patients. The bleeding events of the two groups were recorded during the follow-up period, and the two groups were balanced by propensity score weighting.A total of 198 patients with NVAF and body weight ≤60kg receiving rivaroxaban anticoagulation therapy were enrolled, including 65 patients in the standard-dose group (15-20 mg) and 133 patients in the low-dose group (10-15 mg). In this study, only 24.1% (65/241) of the patients followed the standard dose of rivaroxaban. There was no significant difference in the incidence of bleeding events between the two groups after the balance of baseline characteristics (age) (P>0.05). This was also consistent in patients weighing less than 50kg.In the real world, in lower-weight patients with nonvalvular atrial fibrillation, a reduced dose of rivaroxaban did not reduce the risk of bleeding, and this was consistent in patients weighing less than 50kg.

    Keywords: Low body weight, rivaroxaban, Nonvalvular atrial fibrillation, Hemorrhage, low dose

    Received: 12 Sep 2024; Accepted: 29 Oct 2024.

    Copyright: © 2024 Liu, Lai, Chen and Xiong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hengli Lai, Department of Cardiology, Jiangxi Provincial People's Hospital, Nanchang, 330006, Jiangxi Province, China
    Ganwei Xiong, The First People's Hospital of Xiushui County, Jiujiang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.